Welcome to our dedicated page for Vericel Corporation news (Ticker: VCEL), a resource for investors and traders seeking the latest updates and insights on Vericel Corporation stock.
Vericel Corporation (NASDAQ:VCEL) is a leading biopharmaceutical company dedicated to developing advanced, patient-specific cellular therapies for severe diseases and conditions. Founded in 1989 as Aastrom Biosciences, Vericel focuses on therapies for sports medicine and severe burn care. The company currently markets three key products in the United States: MACI®, Epicel®, and NexoBrid®.
MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product used to repair symptomatic, full-thickness cartilage defects in the knee. Epicel® (cultured epidermal autografts) serves as a permanent skin replacement for patients with deep dermal or full-thickness burns covering 30% or more of the total body surface area. Vericel also holds exclusive North American rights to NexoBrid® (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes that removes eschar in adults with deep partial- and full-thickness burns.
Vericel has shown strong financial performance with consistent revenue growth across its product lines. In the second quarter of 2023, Vericel reported a 24% increase in total net revenue to $45.9 million. Gross profit for the same period was $29.9 million, representing 65% of net revenue.
The company is poised for continued success with its plans to launch arthroscopic MACI, expected to further increase revenue growth in 2024. Additionally, the U.S. commercial availability of NexoBrid signifies a major expansion of Vericel's burn care franchise, offering a novel treatment for severe thermal burns by selectively targeting eschar while preserving viable tissue.
Vericel's mission is to help patients with severe conditions through innovative therapies. The company's commitment to growth and development is evident in its financial health, partnerships, and strategic initiatives aimed at expanding its market presence and enhancing its product portfolio.
Vericel Corporation (NASDAQ:VCEL) reported a 26% revenue growth in 2021, achieving total net revenue of $156.2 million. For Q4 2021, net revenue was $47.6 million, a 5% increase year-over-year. While MACI revenue reached $111.6 million and Epicel revenue hit $41.5 million, the company reported a net loss of $7.5 million for the year. Looking ahead, Vericel anticipates 2022 revenues between $178 million and $189 million with a gross margin of approximately 70%. A conference call is scheduled for today at 8:30 AM ET.
Vericel Corporation (NASDAQ:VCEL) announced a conference call on February 24, 2022 at 8:30 AM EST to discuss its fourth-quarter 2021 financial results and business highlights. The call will be accessible via the Investor Relations section of their website. Vericel specializes in advanced therapies in sports medicine and severe burn care, offering products like MACI® and Epicel®. A replay of the call will be available until February 28, 2022.
Vericel Corporation (NASDAQ:VCEL) has announced a long-term lease for a new 125,000 square foot facility in Burlington, Massachusetts, which will serve as its advanced cell therapy manufacturing and corporate headquarters. This state-of-the-art facility will enhance the company’s manufacturing capacity for its products MACI® and Epicel®, supporting long-term revenue growth. Expected completion is in 2024, with production starting in 2025. The facility aims to meet LEED Gold and Fitwel Level 2 certifications, reinforcing the company’s commitment to environmentally responsible operations.
Vericel Corporation (NASDAQ:VCEL) announced that its President and CEO, Nick Colangelo, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 7:30 a.m. Eastern Time. This esteemed conference is a significant platform for healthcare companies to share insights and updates.
A webcast of the presentation will be accessible on the Investor Relations section of Vericel's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ:VCEL) announced that President and CEO Nick Colangelo will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18 at 10:00 AM ET. This event aims to showcase advancements in medical technology and health services.
A webcast of the presentation will be accessible on the Investor Relations section of the Vericel website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®.
Vericel Corporation (NASDAQ: VCEL) reported third quarter 2021 net revenue of $34.5 million, a 7% increase from $32.3 million in Q3 2020. Year-to-date revenue rose 38% to $108.6 million. Notably, MACI revenue was $23.9 million, and Epicel revenue was $9.8 million. The company faced a net loss of $4.9 million or $0.11 per share, contrasting with net income of $3.6 million in Q3 2020. Gross margin decreased to 64%, down from 70% the previous year. The company adjusted its full-year revenue guidance to reflect a projected increase of 27%-30%.
Vericel Corporation (NASDAQ:VCEL) has announced a webcast and conference call to discuss its third-quarter 2021 financial results and business highlights. The call is scheduled for November 9, 2021, at 8:30 AM EDT. Investors can access the call live via the company's Investor Relations website. Vericel operates in advanced therapies for sports medicine and severe burn care, marketing two cell therapy products: MACI® and Epicel®. The company also holds the exclusive North American commercial rights for NexoBrid®, aimed at severe burn treatment.
Vericel Corporation (NASDAQ:VCEL) announced that Nick Colangelo, President and CEO, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference. The event is scheduled for Monday, September 13, 2021, at 4:15 p.m. Eastern Time. Investors can access the webcast through the Investor Relations section of Vericel's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI® and Epicel®. For further details, visit www.vcel.com.
Vericel Corporation (NASDAQ:VCEL) has appointed Patrick J. Fowler as Senior Vice President of Corporate Development and Strategy, effective immediately. With over 15 years of experience in business development within the biotech sector, Fowler previously led strategy and operations at Sanofi, enhancing corporate growth and development strategies. The company anticipates Fowler's expertise will drive growth and enhance its innovative product portfolio, which includes MACI® and Epicel® for sports medicine and burn care.
Vericel Corporation (NASDAQ:VCEL) reported a **97%** increase in **total net revenue** for Q2 2021, reaching **$39.5 million**. Key products contributed with **MACI®** revenue at **$26.5 million** and **Epicel®** at **$12.2 million**. The company improved its gross margin to **68%** from **57%** year-over-year. Although net loss decreased to **$3.8 million** from **$8.3 million**, operating expenses rose to **$30.6 million**. Cash reserves increased to **$116 million**. Full-year revenue guidance was raised to **$168-$171 million**, indicating strong business momentum.
FAQ
What is the current stock price of Vericel Corporation (VCEL)?
What is the market cap of Vericel Corporation (VCEL)?
What products does Vericel Corporation market?
What is MACI® used for?
What is Epicel®?
What is NexoBrid®?
How did Vericel perform financially in the second quarter of 2023?
What are Vericel's financial prospects for 2024?
When was Vericel Corporation founded?
What is the significance of NexoBrid®'s commercial availability in the U.S.?
What is Vericel's mission?
What is the significance of Vericel's recent financial performance?
